Skip to main content

RPRX Royalty Pharma plc

Healthcare

66.52 -0.66 -0.99% Close 11/2
Since 2024-12-02 +164.1%
Open
66.97
High
67.10
Low
66.43
Prev close
67.18
Volume
2.7M
Amplitude
1.00%
P/E
38.6
P/B
4.4
Revenue YoY (TTM)
+10.0%
52W 36.03 67.71

Is Royalty Pharma plc a buy? Fundamentals and valuation first

As of 2026-10-30

Quality: Strong, Momentum: Strong, Risk / liquidity: Strong; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Top, but Price / book is Pricey.
TTM P/E 38.61 76th percentile Pricey
Price / book 4.38 80th percentile Pricey
Free-cash-flow yield (%) 9.95 81th percentile Top
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Strong FCF margin, TTM is Top; ROE, TTM is Good.
ROE, TTM (%) 11.93 70th percentile Good
Operating margin, TTM (%) 62.34 94th percentile Top
FCF margin, TTM (%) 117.37 96th percentile Top
Quality Factor Investing: A US Quality Value Backtest
Growth Neutral Revenue growth, TTM YoY is Good, but Diluted EPS growth, TTM YoY is Average.
Revenue growth, TTM YoY (%) 10.01 61th percentile Good
Diluted EPS growth, TTM YoY (%) -13.43 49th percentile Average
Momentum Strong All 2 indicators are Top.
60-day return (%) 17.79 91th percentile Top
240-day return (%) 73.91 92th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Strong 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 192,382,079 92th percentile Top
60-day annualized volatility (%) 25.05 28th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

Royalty Pharma plc (RPRX) today

3 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Royalty Pharma plc to every stock like it

AI finds several complementary traits of Royalty Pharma plc across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Royalty Pharma plc

Royalty Pharma plc (RPRX) peers and tracking

Watchlist

This page refreshes daily after the close. Add Royalty Pharma plc to your watchlist to track signal changes on your next visit.

Royalty Pharma plc (RPRX) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

11 historical occurrences (since 2022-08-12)

Average forward return after 52-week adjusted-price high

20-day: Win 80%, Sample 10, Median +3.81%, Excess +2.85%, Beat mkt rate 70%

60-day: Win 88.9%, Sample 9, Median +7.17%, Excess +8.03%, Beat mkt rate 66.7%

120-day: Win 87.5%, Sample 8, Median +21.81%, Excess +13.97%, Beat mkt rate 87.5%

120 days after: historical avg +22.4%

20-day +4.09%
60-day +9.62%
120-day +22.4%
20-day
60-day
120-day
Win
80%
88.9%
87.5%
Sample
10
9
8
Median
+3.81%
+7.17%
+21.81%
Excess
+2.85%
+8.03%
+13.97%
Beat mkt rate
70%
66.7%
87.5%

Over 8 occurrences, 120-day forward avg gained 22.4%, beat the market by 13.97 pts; win rate 87.5%.

Top-quintile 6-month momentum

Active · now 87.35%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
9 historical occurrences (since 2022-04-08)

Average forward return after Top-quintile 6-month momentum

20-day: Win 62.5%, Sample 8, Median +3.99%, Excess +3.47%, Beat mkt rate 100%

60-day: Win 85.7%, Sample 7, Median +4.41%, Excess +5.78%, Beat mkt rate 71.4%

120-day: Win 71.4%, Sample 7, Median +9.75%, Excess +5.75%, Beat mkt rate 85.7%

120 days after: historical avg +9.73%

20-day +1.4%
60-day +6.78%
120-day +9.73%
20-day
60-day
120-day
Win
62.5%
85.7%
71.4%
Sample
8
7
7
Median
+3.99%
+4.41%
+9.75%
Excess
+3.47%
+5.78%
+5.75%
Beat mkt rate
100%
71.4%
85.7%

Over 7 occurrences, 120-day forward avg gained 9.73%, beat the market by 5.75 pts; win rate 71.4%.

Filed revenue acceleration

Active · now 10.01%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

1 historical occurrences (since 2026-08-05)

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 290+36.4% +33.5% 100% +21.9%
20-40 137+56.6% +57.4% 100% +38.3%
40-60 3Insufficient data
60-80 You are here8Insufficient data
80-100 69-0.8% -1.3% 42% -27.3%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 38.61, placing it in the 71.9 own-history percentile, inside the 60-80 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+14.4%
Win rate 86.2% Excess +5.5%
275d
+33.8%
Win rate 100% Excess +23.3%
128d
Now
-2.9%
Win rate 19.1% Excess -16.4%
47d
60-day momentum down
+15.4%
Win rate 68% Excess +9.8%
147d
Insufficient data
(0d)
+3.1%
Win rate 86.7% Excess -14%
30d

Currently in “Expensive (own-history top third) × 60-day momentum up”: across 47 historical days, 120-day forward avg declined 2.9%, win rate 19.1%, lagged the market by 16.4%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

11 times historically; 60-day forward avg +4.08%, win rate 63.6%, beating the market by +0.56 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.